Impact of Disability on Burden of Illness Among Patients With Chronic Inflammatory Demyelinating Polyneuropathy in the United States
Author(s)
Swapna Karkare, MS1, CECILE BLEIN, PhD2, Arash Mahajerin, MD, MSCr3, Rucha Kulkarni, MPH4, Tania Banerji, MPH, MS4, Namith Dharani, BS5, Aazim A. Shaukathali, BS5, Anthony Nguyen, PhD6, Amit Goyal, MBA7;
1Argenx, Health Economics & Outcomes Research, Boston, MA, USA, 2Argenx, Health Economics & Outcomes Research, Ghent, Belgium, 3Argenx, Medical Affairs, Boston, MA, USA, 4ZS Associates, Medical & Evidence, Bethesda, MD, USA, 5ZS Associates, Medical & Evidence, Bengaluru, India, 6ZS Associates, Medical & Evidence, Evanston, IL, USA, 7ZS Associates, Medical & Evidence, Princeton, NJ, USA
1Argenx, Health Economics & Outcomes Research, Boston, MA, USA, 2Argenx, Health Economics & Outcomes Research, Ghent, Belgium, 3Argenx, Medical Affairs, Boston, MA, USA, 4ZS Associates, Medical & Evidence, Bethesda, MD, USA, 5ZS Associates, Medical & Evidence, Bengaluru, India, 6ZS Associates, Medical & Evidence, Evanston, IL, USA, 7ZS Associates, Medical & Evidence, Princeton, NJ, USA
Presentation Documents
OBJECTIVES: Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) suffer from progressive worsening of functional status and disability related to mobility loss. The objective of this analysis was to evaluate the economic burden among “patients with CIDP and disability” compared to “patients with CIDP without disability” in the United States (US).
METHODS: A retrospective cohort study was conducted using Optum's de-identified Market Clarity Data (Market Clarity) from January 2016 - December 2023. Patients with confirmed CIDP were identified using a previously published algorithm. Among patients with CIDP, those with disability (defined by walker, cane, crutch or wheelchair use-related claim) after the first confirmed CIDP diagnosis and before December 2022 (first claim is index) with continuous enrollment 1 year pre-/post-index were identified. Controls were defined as patients with CIDP without disability. All-cause costs and healthcare resource utilization (HCRU) over the 1-year follow-up were compared between the two cohorts using inverse probability treatment weighting. Subgroup analysis comparing outcomes among patients with CIDP with and without wheelchair use was also conducted.
RESULTS: 554 and 708 patients with CIDP were identified with and without disability, respectively. Patients with disability had over 1.8 times total adjusted all-cause healthcare costs compared to their controls, driven by high inpatient costs (mean total, inpatient and outpatient costs compared to controls: $117,165 vs $64,381, $34,752 vs $6,053 and $29,400 vs $17,103, respectively; all p<0.001). Patients with disability also had higher utilization across all care settings, with outpatient care being the greatest driver. Subgroup analysis focusing on patients with and without wheelchair use mirrored these results.
CONCLUSIONS: Based on US claims, patients with CIDP and disability experience a significantly higher economic burden compared to those without disability, with wheelchair use being a major cost driver. These findings underscore the importance of therapies with potential to reverse disease progression and reduce economic burden.
METHODS: A retrospective cohort study was conducted using Optum's de-identified Market Clarity Data (Market Clarity) from January 2016 - December 2023. Patients with confirmed CIDP were identified using a previously published algorithm. Among patients with CIDP, those with disability (defined by walker, cane, crutch or wheelchair use-related claim) after the first confirmed CIDP diagnosis and before December 2022 (first claim is index) with continuous enrollment 1 year pre-/post-index were identified. Controls were defined as patients with CIDP without disability. All-cause costs and healthcare resource utilization (HCRU) over the 1-year follow-up were compared between the two cohorts using inverse probability treatment weighting. Subgroup analysis comparing outcomes among patients with CIDP with and without wheelchair use was also conducted.
RESULTS: 554 and 708 patients with CIDP were identified with and without disability, respectively. Patients with disability had over 1.8 times total adjusted all-cause healthcare costs compared to their controls, driven by high inpatient costs (mean total, inpatient and outpatient costs compared to controls: $117,165 vs $64,381, $34,752 vs $6,053 and $29,400 vs $17,103, respectively; all p<0.001). Patients with disability also had higher utilization across all care settings, with outpatient care being the greatest driver. Subgroup analysis focusing on patients with and without wheelchair use mirrored these results.
CONCLUSIONS: Based on US claims, patients with CIDP and disability experience a significantly higher economic burden compared to those without disability, with wheelchair use being a major cost driver. These findings underscore the importance of therapies with potential to reverse disease progression and reduce economic burden.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
SA46
Topic
Study Approaches
Disease
SDC: Neurological Disorders, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)